ArticleAmerican journal of translational research2015
Notch-Hes pathway mediates the impaired osteogenic differentiation of bone marrow mesenchymal stromal cells from myelodysplastic syndromes patients through the down-regulation of Runx2.
Article in American journal of translational research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Bone marrow microenvironment reprogramming in myelodysplastic neoplasms: from pathological mechanisms to targeted therapeutic strategies.Frontiers in immunology · 2026Review
- AML alters bone marrow stromal cell osteogenic commitment via Notch signaling.Frontiers in immunology · 2023Article
- Article
- Rutin promotes osteogenic differentiation of periodontal ligament stem cells through the GPR30-mediated PI3K/AKT/mTOR signaling pathway.Experimental biology and medicine (Maywood, N.J.) · 2020Article
- TGF‑β1 promotes the osteoinduction of human osteoblasts via the PI3K/AKT/mTOR/S6K1 signalling pathway.Molecular medicine reports · 2019Article
- Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells.Cell death & disease · 2018Article
- Article
- Hairy/enhancer of Split Homologue-1 Suppresses Vascular Endothelial Growth Factor-induced Angiogenesis via Downregulation of Osteopontin Expression.Scientific reports · 2017Article
- Loss of Notch3 Signaling Enhances Osteogenesis of Mesenchymal Stem Cells from Mandibular Torus.Journal of dental research · 2017Article
- Icariside II promotes the osteogenic differentiation of canine bone marrow mesenchymal stem cells via the PI3K/AKT/mTOR/S6K1 signaling pathways.American journal of translational research · 2017Article
- Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?International journal of molecular sciences · 2016Review
- [The consensus of Chinese experts on molecular biological technology of blood disease diagnosis].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have demonstrated that bone marrow mesenchymal stromal cells (BMMSCs) from patients with myelodysplastic syndromes (MDS) display defective proliferative potential and impaired osteogenic differentiation ability. However, the underlying mechanisms are unclear. In the present study, the impaired osteogenic differentiation potential of BMMSCs was found in cases with RARS (83.3%), RCMD (75.0%), RAEB I (44.4%), RAEB II (40%). We also observed that MDS-BMMSCs with impaired osteogenic differentiation potential exhibited accelerate senescence and decreased hematopoietic supporting function. Further, we found that an abnormal activation of Notch-Hes signaling pathway in MDS-BMMSCs. By overexpression of Notch intracellular domain (NICD) in BMMSCs from healthy donors, we confirmed that Notch signaling pathway negatively regulated BMMSCs osteogenesis through inhibition of Runx2 transcriptional activity. Importantly, treatment with DAPT, a γ-secretase inhibitor of Notch signaling reversed the osteogenic differentiation in MDS-BMMSCs. Collectively, we provide evidence that activation of Notch-Hes signaling pathway is involved in the impaired osteogenic differentiation of MDS-BMMSCs and support the concept of a primary BMMSCs defect that might have a contributory effect in MDS pathogenesis.
Indexed as
Identifiers
26692937PMC4656770W2216719256What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.